Molecular Partners AGMLLCF 25 PB Ratio is 1.55 as of Jun. 25, 2026, which is 53% above its 10-year median of 1.01. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.43 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,233 Biotechnology companies, Molecular Partners AG ranks better than 67.56% on this metric.
Molecular Partners AG stock PB Ratio (=1.7) is close to 3-year high of 1.76.
The historical rank and industry rank for Molecular Partners AG's PB Ratio or its related term are showing as below:
MLLCF'
s PB Ratio Range Over the Past 10 Years
Min: 0.51 Med: 1.01 Max: 8.43
Current: 1.69
During the past 13 years, Molecular Partners AG's highest PB Ratio was 8.43. The lowest was 0.51. And the median was 1.01.
MLLCF's PB Ratio is ranked better than 67.56% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs MLLCF: 1.69
During the past 12 months, Molecular Partners AG's average Book Value Per Share Growth Rate was -47.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -31.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -6.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -6.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Molecular Partners AG was 38.30% per year. The lowest was -31.00% per year. And the median was -9.00% per year.
Back to Basics: PB Ratio
Molecular Partners AG (OTCPK:MLLCF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Molecular Partners AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Molecular Partners AG (MLLCF) has a PB Ratio of 1.55 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Molecular Partners AG and its competitors. This is 53% above median its historical median of 1.01. Over the past decade, Molecular Partners AG's PB Ratio has ranged from 0.51 to 8.43. According to the industry distribution chart, Molecular Partners AG ranks #400 out of 1233 companies in the Biotechnology industry, placing it in the top 32.4%.
Is Molecular Partners AG's PB Ratio too high?
Molecular Partners AG's current PB Ratio of 1.55 is 53% above median its 10-year median of 1.01. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 8.43. The Biotechnology industry median PB Ratio is 2.83. Molecular Partners AG's value of 1.55 is 45.2% below this industry median. Based on the distribution chart, Molecular Partners AG ranks #400 out of 1233 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #400 out of 1233 companies for PB Ratio. This puts Molecular Partners AG in the upper half of its industry. The industry median PB Ratio is 2.83. Molecular Partners AG's value of 1.55 is 45.2% below this benchmark. Historically, Molecular Partners AG's own PB Ratio has ranged from 0.51 to 8.43 over the past decade. While the company's 10-year median is 1.01 vs. the industry median of 2.83, Molecular Partners AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Molecular Partners AG's current PB Ratio of 1.55 is 45.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Molecular Partners AG and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current PB Ratio is 1.55, which is 53% above median its own 10-year median of 1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.43, compared to a current price of $3.60 — trading 737.2% above its estimated fair value. The current PB Ratio is 1.55, which is 53% above median its 10-year median of 1.01 and 45.2% below the Biotechnology industry median of 2.83. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current PB Ratio is 1.55 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.60 is trading 737.2% above its estimated GF Value™ of $0.43.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
PB Ratio: 1.55 (53% above median its 10-year median of 1.01)
GF Value™: $0.43 vs. price of $3.60 (737.2% above fair value)
Industry Position: 45.2% below the Biotechnology median (#400 of 1233)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score
Get the complete analysis for MLLCF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
